Hofseth BioCare ASA (HOFBF)
USD 0.1
(0.0%)
USD 0.1
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 348.97 Million USD | 1201.56% |
| 2022 | 26.81 Million NOK | -14.1% |
| 2021 | 31.21 Million NOK | 36.79% |
| 2020 | 22.81 Million NOK | 14.41% |
| 2019 | 19.94 Million NOK | -80.43% |
| 2018 | 101.9 Million NOK | -30.75% |
| 2017 | 147.15 Million NOK | 39.1% |
| 2016 | 105.79 Million NOK | -34.21% |
| 2015 | 160.8 Million NOK | 15.75% |
| 2014 | 138.91 Million NOK | -2.89% |
| 2013 | 143.05 Million NOK | 32.55% |
| 2012 | 107.92 Million NOK | 185.2% |
| 2011 | 37.84 Million NOK | 103.55% |
| 2010 | 18.59 Million NOK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 23.2 Million USD | 5.5% |
| 2024 Q1 | 21.71 Million USD | -32.65% |
| 2023 Q2 | 27.38 Million USD | 2.98% |
| 2023 Q3 | 28.76 Million USD | 5.04% |
| 2023 Q4 | 34.26 Million USD | 19.1% |
| 2023 Q1 | 26.59 Million USD | -0.81% |
| 2023 FY | 348.97 Million USD | 1201.56% |
| 2022 Q4 | 26.81 Million NOK | 24.03% |
| 2022 Q1 | 32.91 Million NOK | 5.44% |
| 2022 Q2 | 30.36 Million NOK | -7.75% |
| 2022 Q3 | 21.61 Million NOK | -28.8% |
| 2022 FY | 26.81 Million NOK | -14.1% |
| 2021 Q1 | 24.08 Million NOK | -87.67% |
| 2021 FY | 31.21 Million NOK | 36.79% |
| 2021 Q2 | 28.38 Million NOK | 17.83% |
| 2021 Q4 | 31.21 Million NOK | 2.31% |
| 2021 Q3 | 30.5 Million NOK | 7.49% |
| 2020 FY | 22.81 Million NOK | 14.41% |
| 2020 Q1 | 170.88 Million NOK | -2.5% |
| 2020 Q2 | 203.39 Million NOK | 19.03% |
| 2020 Q3 | 217.82 Million NOK | 7.09% |
| 2020 Q4 | 195.37 Million NOK | -10.31% |
| 2019 Q4 | 175.26 Million NOK | -5.78% |
| 2019 Q1 | 178.3 Million NOK | 74.98% |
| 2019 Q2 | 180.35 Million NOK | 1.15% |
| 2019 FY | 19.94 Million NOK | -80.43% |
| 2019 Q3 | 186.02 Million NOK | 3.14% |
| 2018 Q3 | 86.39 Million NOK | -44.31% |
| 2018 Q2 | 155.12 Million NOK | 13.4% |
| 2018 Q1 | 136.79 Million NOK | -7.04% |
| 2018 FY | 101.9 Million NOK | -30.75% |
| 2018 Q4 | 101.9 Million NOK | 17.95% |
| 2017 Q4 | 147.15 Million NOK | 45.97% |
| 2017 Q3 | 100.81 Million NOK | 24.99% |
| 2017 Q2 | 80.65 Million NOK | -20.72% |
| 2017 FY | 147.15 Million NOK | 39.1% |
| 2017 Q1 | 101.73 Million NOK | -3.84% |
| 2016 Q4 | 105.79 Million NOK | -7.14% |
| 2016 FY | 105.79 Million NOK | -34.21% |
| 2016 Q3 | 113.92 Million NOK | -37.25% |
| 2016 Q2 | 181.56 Million NOK | 13.41% |
| 2016 Q1 | 160.08 Million NOK | -0.44% |
| 2015 Q2 | 152.48 Million NOK | -0.29% |
| 2015 FY | 160.8 Million NOK | 15.75% |
| 2015 Q3 | 154.63 Million NOK | 1.41% |
| 2015 Q1 | 152.93 Million NOK | 10.09% |
| 2015 Q4 | 160.8 Million NOK | 3.99% |
| 2014 Q1 | 162.68 Million NOK | 13.73% |
| 2014 FY | 138.91 Million NOK | -2.89% |
| 2014 Q4 | 138.91 Million NOK | 8.41% |
| 2014 Q2 | 107.77 Million NOK | -33.76% |
| 2014 Q3 | 128.14 Million NOK | 18.9% |
| 2013 Q4 | 143.05 Million NOK | 6.58% |
| 2013 Q3 | 134.22 Million NOK | 4.92% |
| 2013 FY | 143.05 Million NOK | 32.55% |
| 2013 Q2 | 127.93 Million NOK | -5.99% |
| 2013 Q1 | 136.07 Million NOK | 26.09% |
| 2012 Q1 | 40.83 Million NOK | 7.92% |
| 2012 FY | 107.92 Million NOK | 185.2% |
| 2012 Q2 | 55.44 Million NOK | 35.78% |
| 2012 Q4 | 107.92 Million NOK | 25.3% |
| 2012 Q3 | 86.13 Million NOK | 55.34% |
| 2011 FY | 37.84 Million NOK | 103.55% |
| 2011 Q3 | 30.75 Million NOK | 0.0% |
| 2011 Q4 | 37.84 Million NOK | 23.05% |
| 2010 FY | 18.59 Million NOK | 0.0% |
| 2010 Q4 | 18.59 Million NOK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -554.683% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -3542.018% |
| SQZ Biotechnologies Company | 50.03 Million USD | -597.414% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -381.543% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -491.349% |
| Mesoblast Limited | 188.44 Million USD | -85.189% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -8961.038% |
| Genus plc | 485 Million USD | 28.046% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -5872.987% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -13768.582% |
| Marizyme, Inc. | 26.67 Million USD | -1208.228% |
| ContraFect Corporation | 32.53 Million USD | -972.758% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -9083.658% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -17513.566% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -9017.322% |
| Intellipharmaceutics International Inc. | 12 Million USD | -2806.035% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -2862.924% |
| MultiCell Technologies, Inc. | 1617.67 USD | -21572841.329% |
| Accustem Sciences Inc. | 1.07 Million USD | -32235.655% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -350.778% |
| EV Biologics, Inc. | 2.11 Million USD | -16399.651% |
| Q BioMed Inc. | 8.13 Million USD | -4190.933% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -320.786% |
| Neon Bloom, Inc. | 1.22 Million USD | -28359.901% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -6681.512% |
| Biomind Labs Inc. | 1.49 Million USD | -23186.815% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | -42.981% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -1796.273% |
| Skye Bioscience, Inc. | 14.07 Million USD | -2379.913% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -17261.016% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -245495.552% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -3586.688% |
| IMV Inc. | 37.93 Million USD | -819.993% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -173421.251% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -5973.614% |
| GB Sciences, Inc. | 5.41 Million USD | -6341.63% |
| Alpha Cognition Inc. | 7.16 Million USD | -4770.761% |
| HST Global, Inc. | 593.59 Thousand USD | -58690.956% |
| CSL Limited | 18.62 Billion USD | 98.126% |
| Halberd Corporation | 728.71 Thousand USD | -47789.378% |
| Enzolytics Inc. | 365.26 Million USD | 4.46% |
| Resverlogix Corp. | 67.39 Million USD | -417.804% |
| Affymax, Inc. | 8.87 Million USD | -3833.931% |
| SYBLEU INC | 681.41 Thousand USD | -51114.021% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -41507.927% |
| argenx SE | 444.95 Million USD | 21.569% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -365.802% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -20260.502% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -2831.833% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -9421.511% |
| AVAX Technologies, Inc. | 3.99 Million USD | -8638.139% |
| Zenith Capital Corp. | 27.56 Thousand USD | -1265738.442% |
| Genscript Biotech Corporation | 1.32 Billion USD | 73.679% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -146128.012% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -9245.217% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -51157.575% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -193.946% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -3759.45% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -521316.725% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -24238.412% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -594.292% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -12769.661% |
| BioStem Technologies, Inc. | 15.9 Million USD | -2094.192% |
| ONE Bio Corp. | 27.49 Million USD | -1169.208% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -74997.859% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -1272013.877% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -27614.497% |
| Agentix Corp. | 2.51 Million USD | -13800.472% |
| LadRx Corporation | 2.2 Million USD | -15758.876% |
| Cell Source, Inc. | 15.8 Million USD | -2107.79% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -780683.515% |
| Regen BioPharma, Inc. | 5.45 Million USD | -6294.349% |
| Regen BioPharma, Inc. | 5.45 Million USD | -6294.349% |
| NovAccess Global Inc. | 7.86 Million USD | -4339.523% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -1310.243% |
| Itoco Inc. | 1.65 Million USD | -21009.929% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -16910.38% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -5669.202% |
| Kadimastem Ltd | 3.5 Million USD | -9856.983% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -82681.188% |
| CytoDyn Inc. | 127.89 Million USD | -172.866% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -834797.964% |
| Mobile Lads Corp. | 1.31 Million USD | -26468.694% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -22179.375% |
| Qrons Inc. | 1.48 Million USD | -23341.657% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -3059.528% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -43048.07% |
| Rebus Holdings, Inc. | 5.24 Million USD | -6557.364% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -5619.181% |
| International Stem Cell Corporation | 5.27 Million USD | -6513.208% |
| Bioxytran, Inc. | 3.24 Million USD | -10639.468% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -55664.458% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -7458.362% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -751.251% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -1467.388% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -17130.238% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -6270.555% |
| Neutra Corp. | 973.52 Thousand USD | -35746.801% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -1102.754% |
| PureTech Health plc | 125.58 Million USD | -177.887% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -9188.459% |
| IXICO plc | 1.9 Million USD | -18264.493% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -1599.932% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -237.752% |
| CSL Limited | 18.62 Billion USD | 98.126% |
| Cellectis S.A. | 249.36 Million USD | -39.945% |